Personalised therapy in pancreatic carcinoma – a forthcoming opportunity?

Iga Płachta; Marek Durlik

doi:10.5114/pg.2026.160362

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

1/2026
vol. 21

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł przeglądowy

Personalised therapy in pancreatic carcinoma – a forthcoming opportunity?

Iga Płachta

¹

,

Marek Durlik

¹

Department of Gastroenterological Surgery and Transplantology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland

Gastroenterology Rev 2026; 21 (1): 13–18

DOI: https://doi.org/10.5114/pg.2026.160362

Data publikacji online: 2026/03/08

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

Pancreatic cancer remains the leading cause of cancer-related mortality. Despite overall advancements in oncological treatment, therapeutic approach remains limited, especially for advanced disease. Precision medicine, basing on the patient’s unique characteristics, including environment, lifestyle, genetics, and disease profile, may complete the cancer management. Starting from the current therapeutic algorithms, this review explores the potential role of personalised treatment as a key to improve the outcomes. Molecular classification based on identification of genetic mutations aids better therapy selection in view of the disease heterogeneity. Patient-derived organoids help in adjusting the current treatment standards to specific tumours, assessing the potential treatment efficacy before the introduction of therapy, whereas the mRNA vaccines, as the novel adjuvant approach, may support the achievement of long-term survival. The proposed opportunities could facilitate the treatment strategies, and continued research is essential for improving patient survival rates.

Personalised therapy in pancreatic carcinoma – a forthcoming opportunity?

Iga Płachta 1 , Marek Durlik 1

Iga Płachta

¹

,

Marek Durlik

¹